Cargando…

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer

Defining the optimal neoadjuvant strategy in early-stage and locoregional (N2) oncogenic-driven lung cancer remains a major challenge for the scientific community. Whereas significant advances have been achieved with the use of personalized medicine and targeted therapies in advanced stages, we are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reyes, Roxana, Reguart, Noemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867758/ https://www.ncbi.nlm.nih.gov/pubmed/33569340 http://dx.doi.org/10.21037/tlcr-20-780

Ejemplares similares

Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
por: Huynh, Caroline, et al.
Publicado: (2021)

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
por: Pradhan, Monika, et al.
Publicado: (2021)

Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
por: Calvo, Virginia, et al.
Publicado: (2021)

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
por: Hamada, Akira, et al.
Publicado: (2021)

Mediastinal staging for non-small cell lung cancer
por: Leiro-Fernández, Virginia, et al.
Publicado: (2021)

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
por: Casal-Mouriño, Ana, et al.
Publicado: (2021)

Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
por: Alcibar, Olwen Leaman, et al.
Publicado: (2021)

Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
por: Patané, Ana Karina
Publicado: (2021)

Induction treatment in patients with stage III non-small cell lung cancer
por: Palmero, Ramón, et al.
Publicado: (2021)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non‐Small Cell Lung Cancer in U.S. Community Medical Centers
por: Bernicker, Eric H., et al.
Publicado: (2021)

Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapy
por: Tang, Andrew, et al.
Publicado: (2022)

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
por: Wang, Chunsheng, et al.
Publicado: (2023)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
por: Awwad, Amir, et al.
Publicado: (2015)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol
por: Sharma, Anukriti, et al.
Publicado: (2022)

Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects
por: Khadela, Avinash, et al.
Publicado: (2023)

Impact of Radiotherapy Combined With Chemotherapy on Long-Term Outcomes of Patients With Recurrent Nasopharyngeal Carcinoma
por: Li, Ying, et al.
Publicado: (2023)

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer
por: Li, Wenbo, et al.
Publicado: (2023)

Targeted Knockdown of Macrophage Migration Inhibitory Factor Enhances UVB Irradiation-Induced Apoptosis Via Increasing ROS Generation in Oral Squamous Cell Carcinoma
por: Chen, Tian, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

LMAP-20 EVIDENCE-BASED MULTIVARIATE NORMAL TISSUE COMPLICATION PROBABILITY (NTCP) STUDY OF DOMAIN-SPECIFIC COGNITIVE DECLINE AFTER PARTIAL BRAIN RT
por: Hopper, Austin, et al.
Publicado: (2023)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

LMAP-08 MULTI-INSTITUTIONAL CLINICAL OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES FROM GYNECOLOGIC MALIGNANCIES
por: Huang, Christina, et al.
Publicado: (2023)

LMAP-14 EFFECT OF TRANSLATIONAL VARIATION ON DOSE CHANGE ADOPTED FOR CONE-BEAM CT GUIDED FRAME BASED STEREOTACTIC RADIOSURGERY OF BRAIN TUMORS
por: Anbumani, Silambarasan, et al.
Publicado: (2023)

LMAP-06 VOLUMETRIC MODULATED ARC THERAPY CRANIOSPINAL IRRADIATION UTILIZING A VERTEBRAL BODY SPARING APPROACH: AN ALTERNATIVE APPROACH TO IMPROVE ACCESS AND MINIMIZE TOXICITY
por: Perlow, Haley K, et al.
Publicado: (2023)

LMAP-22 STEREOTACTIC RADIOSURGERY FOR PATIENTS WITH BRAIN METASTASES FROM GASTROESOPHAGEAL PRIMARY CANCERS
por: Taori, Suchet, et al.
Publicado: (2023)

LMAP-04 CHOOSING WISELY BETWEEN RADIOTHERAPY DOSE-FRACTIONATION SCHEDULES: THE MOLECULAR GRADED PROGNOSTIC ASSESSMENT (MOLGPA) FOR ELDERLY GLIOBLASTOMA (EGBM-MOLGPA)
por: Lee, Hye In, et al.
Publicado: (2023)

LMAP-09 RECAPITULATING LASER INTERSTITIAL THERMAL THERAPY IN PRECLINICAL BRAIN TUMOR MODELS
por: Haskell-Mendoza, Aden, et al.
Publicado: (2023)

LMAP-11 CYSTIC BRAIN METASTASES OUTCOMES FOLLOWING GAMMA KNIFE RADIOTHERAPY
por: Amidon, Ryan, et al.
Publicado: (2023)

LMAP-19 THE ROLE OF STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM COLORECTAL CANCERS
por: Taori, Suchet, et al.
Publicado: (2023)

LMAP-07 POTENTIAL MECHANISM OF IMMUNE ESCAPE RELATED TO TUMOR-ASSOCIATED MACROPHAGE IN GLIOBLASTOMA AFTER COMBINED THERAPY WITH RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKER
por: Zhang, Chi, et al.
Publicado: (2023)

LMAP-17 FEASIBILITY OF COGNITIVE-SPARING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES: INITIAL REPORT OF PHASE II COG-SRS TRIAL
por: Hopper, Austin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nhhg0qf179pqf3d0pj3guqlmkf